Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions

This study has been completed.
Information provided by:
Sandoz Identifier:
First received: August 13, 2009
Last updated: March 27, 2017
Last verified: August 2009
The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.

Condition Intervention Phase
High Blood Pressure
Migraine Headaches
Chest Pain
Drug: Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
Drug: Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions.

Resource links provided by NLM:

Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence based on AUC and Cmax [ Time Frame: 21 days ]

Enrollment: 34
Study Start Date: July 1994
Study Completion Date: July 1994
Primary Completion Date: July 1994 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
Drug: Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
Active Comparator: 2
Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
Drug: Corgard (1 x 80 mg) Tablets (Bristol Laboratories)


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00960245

Sponsors and Collaborators
Principal Investigator: Terry L. Wolff, D.O. MeritCare Broadway Health Center
  More Information

Responsible Party: Eric Mittleberg, Ph.D, VP of Product Development, Sandoz Inc. Identifier: NCT00960245     History of Changes
Other Study ID Numbers: PRACS P94-102
Study First Received: August 13, 2009
Last Updated: March 27, 2017

Additional relevant MeSH terms:
Chest Pain
Migraine Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Vascular Diseases
Cardiovascular Diseases
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents processed this record on April 28, 2017